Amedeo Smart

Free Medical Literature Service



Peptic Ulcer

  Free Subscription

Articles published in
    February 2024
  1. AN H, Zhong M, Gan H
    Proton pump inhibitors and the risk of inflammatory bowel disease: a Mendelian randomisation study.
    Gut. 2024 Feb 15:gutjnl-2024-331904. doi: 10.1136/gutjnl-2024-331904.
    >> Share

    January 2024
  2. XIAO X, Zhang X, Wang J, Liu Y, et al
    Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study.
    Gut. 2024 Jan 24:gutjnl-2023-330883. doi: 10.1136/gutjnl-2023-330883.
    >> Share

  3. BLACK CJ, Paine PA, Ford AC
    Letter to the editor: Helicobacter pylori eradication, the proof is not in the symptoms-authors' reply.
    Gut. 2024 Jan 12:gutjnl-2024-331892. doi: 10.1136/gutjnl-2024-331892.
    >> Share

    December 2023
  4. NARENDREN A, Tsoi AH, Iqbal A, Glance S, et al
    Rare complication of peptic ulcer disease.
    Gut. 2023 Dec 12:gutjnl-2023-330867. doi: 10.1136/gutjnl-2023-330867.
    >> Share

  5. TOH DE, Lo SW, Tsoi A, Segal JP, et al
    Right tool for the right bleeder.
    Gut. 2023;73:206-207.
    >> Share

    November 2023
  6. ZHU J, Sun C, Li M, Hu G, et al
    Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial.
    Gut. 2023 Nov 22:gutjnl-2023-330168. doi: 10.1136/gutjnl-2023-330168.
    >> Share

  7. LUO S, Ru J, Khan Mirzaei M, Xue J, et al
    Helicobacter pylori infection alters gut virome by expanding temperate phages linked to increased risk of colorectal cancer.
    Gut. 2023 Nov 2:gutjnl-2023-330362. doi: 10.1136/gutjnl-2023-330362.
    >> Share

    September 2023
  8. LIU BD, Udemba SC, Liang K, Tarabichi Y, et al
    Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort st
    Gut. 2023 Sep 22:gutjnl-2023-329651. doi: 10.1136/gutjnl-2023-329651.
    >> Share

    July 2023

  9. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg).
    Gut. 2023 Jul 19:gutjnl-2022-329259. doi: 10.1136/gutjnl-2022-329259.
    >> Share

    June 2023
  10. SJOMINA O, Vangravs R, Leonova E, Polaka I, et al
    Clarithromycin-containing triple therapy for Helicobacter pylori eradication is inducing increased long-term resistant bacteria communities in the gut.
    Gut. 2023 Jun 26:gutjnl-2023-329792. doi: 10.1136/gutjnl-2023-329792.
    >> Share

    May 2023
  11. ARAI J, Niikura R, Hayakawa Y, Hirata Y, et al
    Autoimmune gastritis may be less susceptible to cancer development than Helicobacter pylori-related gastritis based on histological analysis.
    Gut. 2023 May 17:gutjnl-2023-330052. doi: 10.1136/gutjnl-2023-330052.
    >> Share

  12. LEI WY, Lee JY, Chuang SL, Bair MJ, et al
    Eradicating Helicobacter pylori via (13)C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method.
    Gut. 2023 May 17:gutjnl-2023-329871. doi: 10.1136/gutjnl-2023-329871.
    >> Share

    April 2023
  13. RALSER A, Dietl A, Jarosch S, Engelsberger V, et al
    Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature.
    Gut. 2023 Apr 4:gutjnl-2022-328075. doi: 10.1136/gutjnl-2022-328075.
    >> Share

  14. YE BD
    Proton pump inhibitors and the risk of inflammatory bowel disease: cause, protopathic bias or others?
    Gut. 2023 Apr 4:gutjnl-2023-329506. doi: 10.1136/gutjnl-2023-329506.
    >> Share

    March 2023
  15. CHEN PY, Tsai FP, Chen MJ, Yang HY, et al
    Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials.
    Gut. 2023 Mar 31:gutjnl-2023-329826. doi: 10.1136/gutjnl-2023-329826.
    >> Share

  16. ZHANG J, Deng Y, Liu C, Wang H, et al
    'Family-based' strategy for Helicobacter pylori infection screening: an efficient alternative to 'test and treat' strategy.
    Gut. 2023 Mar 7:gutjnl-2023-329696. doi: 10.1136/gutjnl-2023-329696.
    >> Share

  17. MALFERTHEINER P, Megraud F, Rokkas T, Gisbert JP, et al
    Empiric use of standard triple therapy in Helicobacter pylori eradication does not require readjustment in the clarithromycin resistance cut-off point.
    Gut. 2023 Mar 6:gutjnl-2023-329712. doi: 10.1136/gutjnl-2023-329712.
    >> Share

    January 2023
  18. ABRAHAMI D, Pradhan R, Yin H, Yanofsky R, et al
    Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study.
    Gut. 2023 Jan 30:gutjnl-2022-328866. doi: 10.1136/gutjnl-2022-328866.
    >> Share

  19. MEIER B, Schmidt A, Caca K
    Over-the-scope clips versus standard therapy in upper gastrointestinal bleeding.
    Gut. 2023 Jan 27:gutjnl-2022-329296. doi: 10.1136/gutjnl-2022-329296.
    >> Share

  20. ZHOU XZ, Lyu NH, Zhu HY, Cai QC, et al
    Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention.
    Gut. 2023 Jan 23:gutjnl-2022-328965. doi: 10.1136/gutjnl-2022-328965.
    >> Share

    December 2022
  21. HSU PI, Chuah SK, Yamaoka Y, Wu DC, et al
    Cut-off value of clarithromycin resistance in the treatment of Helicobacter pylori infection: how low is low?
    Gut. 2022 Dec 30:gutjnl-2022-329253. doi: 10.1136/gutjnl-2022-329253.
    >> Share

  22. BURGOS-SANTAMARIA D, Nyssen OP, Gasbarrini A, Vaira D, et al
    Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg).
    Gut. 2022 Dec 5:gutjnl-2022-328232. doi: 10.1136/gutjnl-2022-328232.
    >> Share

    November 2022
  23. BORNSCHEIN J, Pritchard DM, Malfertheiner P
    Letter to the editor: Helicobacter pylori eradication - the proof is not in the symptoms.
    Gut. 2022 Nov 15. pii: gutjnl-2022-329057. doi: 10.1136/gutjnl-2022-329057.
    >> Share

    October 2022
  24. CHAN S, Pittayanon R, Wang HP, Chen JH, et al
    Use of over-the-scope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size >/=1.5 cm): an open-labelled, multicentre international randomised controlled trial.
    Gut. 2022 Oct 28. pii: gutjnl-2022-327007. doi: 10.1136/gutjnl-2022-327007.
    >> Share

    August 2022
  25. MALFERTHEINER P, Megraud F, Rokkas T, Gisbert JP, et al
    Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.
    Gut. 2022 Aug 8. pii: gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745.
    >> Share

    June 2022
  26. RUGGE M, Bricca L, Guzzinati S, Sacchi D, et al
    Autoimmune gastritis: long-term natural history in naive Helicobacter pylori-negative patients.
    Gut. 2022 Jun 30. pii: gutjnl-2022-327827. doi: 10.1136/gutjnl-2022-327827.
    >> Share

    April 2022
  27. KALAPALA R, Karyampudi A, Nabi Z, Darisetty S, et al
    Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: results from a randomised, sham controlled trial.
    Gut. 2022;71:686-694.
    >> Share

    March 2022
  28. MEIER B, Wannhoff A, Denzer U, Stathopoulos P, et al
    Over-the-scope-clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: a randomised controlled trial (STING-2).
    Gut. 2022 Mar 23. pii: gutjnl-2021-325300. doi: 10.1136/gutjnl-2021-325300.
    >> Share

    January 2022
  29. FORD AC, Tsipotis E, Yuan Y, Leontiadis GI, et al
    Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis.
    Gut. 2022 Jan 12. pii: gutjnl-2021-326583. doi: 10.1136/gutjnl-2021-326583.
    >> Share

    December 2021
  30. DONG C, Lee YH, Tan TY, Yao CC, et al
    Correspondence to proton pump inhibitors and risk of colorectal cancer.
    Gut. 2021 Dec 2. pii: gutjnl-2021-326139. doi: 10.1136/gutjnl-2021-326139.
    >> Share

  31. ABRAHAMI D, Azoulay L
    Response by Abrahami et al to letter regarding article 'Proton pump inhibitors and risk of colorectal cancer'.
    Gut. 2021 Dec 2. pii: gutjnl-2021-326544. doi: 10.1136/gutjnl-2021-326544.
    >> Share

  32. ZERBIB F
    Diagnosis of GORD: is the 'grey area' expanding?
    Gut. 2021;70:2221-2222.
    >> Share

  33. RUSU RI, Fox MR, Tucker E, Zeki S, et al
    Validation of the Lyon classification for GORD diagnosis: acid exposure time assessed by prolonged wireless pH monitoring in healthy controls and patients with erosive oesophagitis.
    Gut. 2021;70:2230-2237.
    >> Share

    November 2021
  34. ZENG R, Sha W, Wang J, Zhuo Z, et al
    Evaluation of proton pump inhibitors and risks of gastric cancer.
    Gut. 2021 Nov 26. pii: gutjnl-2021-326291. doi: 10.1136/gutjnl-2021-326291.
    >> Share

  35. DING SZ, Du YQ, Lu H, Wang WH, et al
    Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition).
    Gut. 2021 Nov 26. pii: gutjnl-2021-325630. doi: 10.1136/gutjnl-2021-325630.
    >> Share

  36. LOOSEN SH, Kostev K, Luedde M, Qvartskhava N, et al
    Long-term use of proton pump inhibitors (PPIs) is associated with an increased risk of type 2 diabetes.
    Gut. 2021 Nov 1. pii: gutjnl-2021-326297. doi: 10.1136/gutjnl-2021-326297.
    >> Share

    October 2021
  37. SHAH S, Halvorson A, McBay B, Dorn C, et al
    Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort.
    Gut. 2021 Oct 18. pii: gutjnl-2021-325701. doi: 10.1136/gutjnl-2021-325701.
    >> Share

    September 2021
  38. GUO CLT, Wong SH, Lau LHS, Lui RNS, et al
    Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study.
    Gut. 2021 Sep 21. pii: gutjnl-2020-323054. doi: 10.1136/gutjnl-2020-323054.
    >> Share

    August 2021
  39. ARAI J, Niikura R, Hayakawa Y, Aoki T, et al
    OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325551. doi: 10.1136/gutjnl-2021-325551.
    >> Share

    July 2021
  40. PATEL J, Berezowski I, Janapala RN, Pourmand A, et al
    Proton pump inhibitors and gastric cancer: a population-based cohort study.
    Gut. 2021 Jul 14. pii: gutjnl-2021-325385. doi: 10.1136/gutjnl-2021-325385.
    >> Share

  41. OSTER P, Vaillant L, Riva E, McMillan B, et al
    Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.
    Gut. 2021 Jul 12. pii: gutjnl-2020-323392. doi: 10.1136/gutjnl-2020-323392.
    >> Share

  42. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
    Gut. 2021 Jul 5. pii: gutjnl-2021-325097. doi: 10.1136/gutjnl-2021-325097.
    >> Share

  43. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of colorectal cancer.
    Gut. 2021 Jul 1. pii: gutjnl-2021-325096. doi: 10.1136/gutjnl-2021-325096.
    >> Share

    June 2021
  44. ONG JS, An J, Han X, Law MH, et al
    Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis.
    Gut. 2021 Jun 29. pii: gutjnl-2020-323906. doi: 10.1136/gutjnl-2020-323906.
    >> Share

    May 2021
  45. SEO SI, Park CH, You SC, Kim JY, et al
    Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Gut. 2021 May 11. pii: gutjnl-2020-323845. doi: 10.1136/gutjnl-2020-323845.
    >> Share

    April 2021
  46. MEGRAUD F, Bruyndonckx R, Coenen S, Wittkop L, et al
    Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community.
    Gut. 2021 Apr 9. pii: gutjnl-2021-324032. doi: 10.1136/gutjnl-2021-324032.
    >> Share

  47. NIENHUSER H, Kim W, Malagola E, Ruan T, et al
    Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice.
    Gut. 2021;70:654-665.
    >> Share

    March 2021
  48. SUNG JJY, Laine L, Kuipers EJ, Barkun AN, et al
    Towards personalised management for non-variceal upper gastrointestinal bleeding.
    Gut. 2021 Mar 1. pii: gutjnl-2020-323846. doi: 10.1136/gutjnl-2020-323846.
    >> Share

    December 2020
  49. SPILLER RC, Jalanka J
    Brachyspira and IBS with diarrhoea: a Helicobacter pylori moment?
    Gut. 2020 Dec 24. pii: gutjnl-2020-323370. doi: 10.1136/gutjnl-2020-323370.
    >> Share

  50. HE Q, Yang M, Qin X, Fan D, et al
    Risk stratification for proton pump inhibitor-associated type 2 diabetes: a population-based cohort study.
    Gut. 2020 Dec 22. pii: gutjnl-2020-323816. doi: 10.1136/gutjnl-2020-323816.
    >> Share

  51. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    >> Share

  52. LEE SW, Yang JM, Yoo IK, Moon SY, et al
    Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323672. doi: 10.1136/gutjnl-2020-323672.
    >> Share

  53. ZHOU J, Wang X, Lee S, Wu WKK, et al
    Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.
    Gut. 2020 Dec 4. pii: gutjnl-2020-323668. doi: 10.1136/gutjnl-2020-323668.
    >> Share

    November 2020
  54. LI GF, An XX, Yu Y, Jiao LR, et al
    Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis.
    Gut. 2020 Nov 10. pii: gutjnl-2020-323366. doi: 10.1136/gutjnl-2020-323366.
    >> Share

    October 2020
  55. LIOU JM, Malfertheiner P, Lee YC, Sheu BS, et al
    Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
    Gut. 2020 Oct 1. pii: gutjnl-2020-322368. doi: 10.1136/gutjnl-2020-322368.
    >> Share

    September 2020
  56. ZHOU X, Zhu H, Chen Y, Li Z, et al
    Role of Helicobacter pylori in gastric diseases pathogenesis cannot be ignored.
    Gut. 2020 Sep 29. pii: gutjnl-2020-322629. doi: 10.1136/gutjnl-2020-322629.
    >> Share

  57. YUAN J, He Q, Nguyen LH, Wong MCS, et al
    Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies.
    Gut. 2020 Sep 28. pii: gutjnl-2020-322557. doi: 10.1136/gutjnl-2020-322557.
    >> Share

    April 2020
  58. WONG GLH, Lau LHS, Ching JYL, Tse YK, et al
    Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
    Gut. 2020;69:652-657.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016